A Systematic Review of Human Challenge Trials, Designs, and Safety
Clinical Infectious Diseases · 18.02.2023 · 76 (4) · 609-619
DOI: 10.1093/cid/ciac820 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Infectious Diseases, online erschienen am 11.10.2022. Verfasst von Jupiter Adams-Phipps und 9 weiteren Autor:innen. Beteiligte Einrichtung: 1Day Sooner Research Team, Lewes, Delaware, USA. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, 1Day Sooner, Center for Effective Altruism’s Long Term Future Fund.
Abstract (Originalsprache)
Background
Few studies have assessed participant safety in human challenge trials (HCTs). Key questions regarding HCTs include how risky such trials have been, how often adverse events (AEs) and serious adverse events (SAEs) occur, and whether risk mitigation measures have been effective.
Methods
A systematic search of PubMed and PubMed Central for articles reporting on results of HCTs published between 1980 and 2021 was performed and completed by 7 October 2021.
Results
Of 2838 articles screened, 276 were reviewed in full. A total of 15 046 challenged participants were described in 308 studies that met inclusion criteria; 286 (92.9%) of these studies reported mitigation measures used to minimize risk to the challenge population. Among 187 studies that reported on SAEs, 0.2% of participants experienced at least 1 challenge-related SAE. Among 94 studies that graded AEs by severity, challenge-related AEs graded “severe” were reported by between 5.6% and 15.8% of participants. AE data were provided as a range to account for unclear reporting. Eighty percent of studies published after 2010 were registered in a trials database.
Conclusions
HCTs are increasingly common and used for an expanding list of diseases. Although AEs occur, severe AEs and SAEs are rare. Reporting has improved over time, though not all papers provide a comprehensive report of relevant health impacts. We found very few severe symptoms or SAEs in studies that reported them, but many HCTs did not report relevant safety data. This study was preregistered on PROSPERO as CRD42021247218.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- 1Day Sooner Research Team, Lewes, Delaware, USA.
- Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
- RAND Corporation, Pardee RAND Graduate School, Santa Monica, California, USA.
- The Ethox Centre & Wellcome Centre for Ethics and the Humanities, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
- Monash Bioethics Centre, Monash University, Clayton, VIC, Australia.
- Royal Melbourne Hospital Department of Medicine, University of Melbourne, Parkville, VIC, Australia.
ORCID-Profile: David Manheim
Förderung
- Wellcome Trust
- 1Day Sooner
- Center for Effective Altruism’s Long Term Future Fund
- National Health and Medical Research Council
Zitieren
APA
Adams-Phipps, J., Toomey, D., Więcek, W., Schmit, V., Wilkinson, J., Scholl, K., Jamrozik, E., Osowicki, J., Roestenberg, M., & Manheim, D. (2023). A Systematic Review of Human Challenge Trials, Designs, and Safety. Clinical Infectious Diseases, 76(4), 609-619. https://doi.org/10.1093/cid/ciac820
Vancouver
Adams-Phipps J, Toomey D, Więcek W, Schmit V, Wilkinson J, Scholl K, et al. A Systematic Review of Human Challenge Trials, Designs, and Safety. Clinical Infectious Diseases. 2023;76(4):609-619. doi:10.1093/cid/ciac820
BibTeX
@article{AdamsPhipps2023,
author = {Adams-Phipps, Jupiter and Toomey, Danny and Więcek, Witold and Schmit, Virginia and Wilkinson, James and Scholl, Keller and Jamrozik, Euzebiusz and Osowicki, Joshua and Roestenberg, Meta and Manheim, David},
title = {A Systematic Review of Human Challenge Trials, Designs, and Safety},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {76},
number = {4},
pages = {609--619},
doi = {10.1093/cid/ciac820}
}
EUVIMED